It all depends which bits you read. Certainly the market has...

It all depends which bits you read. Certainly the market has marked it down and appears to be a bit disappointed in what has been revealed. Probably some of the punters were hoping for greater signs of growth and a lower loss. That includes me. But allowances have to be made at this stage in PEB's growth as a company.
First Covid in the US has not been helpful. The key task of the sales people getting face to face meetings with key urologists has been difficult to achieve given the reluctance to expose medical specialists to potential Covid contacts. So sales opportunities have been limited or difficult until recent months.
Even though PEB managed to get its breakthrough agreement with Kaiser Permante the roll out of the programme within KP was slow again because of Covid concerns
Then of course the fact that the loss increased quite a bit was probably viewed as a negative. However, much of that increase would be in the adding of more sales people to the team and associated costs with the increased size of the sales team. Once they all get up to speed and generate more contacts and therefore sales then the expenditure on the increased sales team will be justified more clearly.
There are positive signs there if you trawl through the information.
Probably, in the absence of any other significant announcement between now and the AGM in July, there will be some information shared at the AGM about how things have been tracking since this insight in May. The next significant official report will be the half year results after the end of September.
I would think and hope that by later this year the stronger growth path will become more obvious.